9.3 Management of Non-Seminoma (Stage I to Metastatic)

9.3 Management of Non-Seminoma (Stage I to Metastatic)

Non-Seminomatous Germ Cell Tumours (NSGCTTs) account for approximately 50% of all testicular malignancies and characteristically affect younger men, with a peak incidence in the third decade of life (median age 25 to 30 years). Approximately 60% to 70% of non-seminomas present as mixed germ cell tumours containing two or more distinct histological components. Unlike seminomas, non-seminomatous neoplasms tend to be biologically more aggressive, demonstrate a higher propensity for early hematogenous and lymphatic dissemination, and frequently contain teratoma, which is entirely insensitive to cytotoxic chemotherapy and ionizing radiation.

---

1. Histopathological Subtypes & Somatic Transformation

Accurate histological classification dictates clinical risk stratification and therapeutic responsiveness across all stages:

Embryonal Carcinoma

• Microscopic Appearance: Highly aggressive, poorly differentiated, primitive epithelioid cells with amphophilic cytoplasm, pleomorphic vesicular nuclei, prominent nucleoli, and brisk mitotic activity. They form solid sheets, papillary projections, or irregular glandular/tubular structures with extensive central geographic necrosis.
• Immunohistochemistry: Strongly positive for CD30, OCT3/4, SOX2, Cytokeratin (AE1/AE3), and SALL4; c-KIT (CD117) is negative.
• Marker Secretion: May produce both AFP (if microscopic yolk sac differentiation exists) and beta-hCG.

Yolk Sac Tumour (Endodermal Sinus Tumour)

• Microscopic Appearance: The most common testicular neoplasm in infants and children <3 years (pure form, excellent prognosis); in adults, it occurs almost exclusively as a component of mixed NSGCTT. Manifests in diverse patterns (reticular/microcystic, festoon, pseudopapillary). Pathognomonic Schiller-Duval bodies (a central single capillary surrounded by a mantle of cuboidal/columnar tumour cells within a microcystic space, mimicking an embryonic glomerulus) are identified in 50% to 75% of cases.
• Immunohistochemistry & Markers: Strongly positive for AFP, Glypican-3, and SALL4. Consistently responsible for marked serum AFP elevations.

Choriocarcinoma

• Microscopic Appearance: Highly malignant, dimorphic population composed of multinucleated syncytiotrophoblasts (large cells with abundant vacuolated eosinophilic cytoplasm producing massive beta-hCG) intermingled with cohesive mononucleated cytotrophoblasts. The tumour is characterized by extensive, destructive vascular invasion and extensive parenchymal hemorrhage.
• Clinical Behavior: Pure choriocarcinoma is exceedingly rare (<1%), but carries the most aggressive clinical course of any germ cell tumour. It bypasses retroperitoneal lymph nodes to undergo early hematogenous metastasis to lungs, liver, brain, and spleen. Massive beta-hCG elevations (>50,000 to >1,000,000 IU/L) frequently cause bilateral gynecomastia and can precipitate acute spontaneous intratumoural alveolar or intracerebral hemorrhage (choriocarcinoma syndrome).

Teratoma (Mature vs Immature) & Somatic Malignant Transformation

• Histology: Composed of differentiated tissues representing one or more embryonic germ cell layers:
  • Ectoderm: Keratinizing squamous epithelium, brain tissue, teeth, hair follicles.
  • Mesoderm: Mature hyaline cartilage, bone, smooth muscle, adipose tissue.
  • Endoderm: Bronchial respiratory epithelium, mucin-secreting intestinal glands.
• Mature vs Immature: Mature teratoma contains fully differentiated adult-like tissues; immature teratoma contains primitive, fetal/embryonic blastema. In postpubertal males, both mature and immature teratomas are biologically malignant and capable of metastasis.
• Chemo-Resistance & Radio-Resistance: Teratomatous elements do not undergo apoptosis in response to cisplatin-based chemotherapy or radiation therapy; they can ONLY be eradicated by complete surgical extirpation.
• Malignant Somatic Transformation: In approximately 2% to 3% of cases, teratomatous elements undergo clonal malignant dedifferentiation into non-germ cell somatic malignancies, such as rhabdomyosarcoma, liposarcoma, enteric adenocarcinoma, squamous cell carcinoma, or embryonic-type neuroectodermal tumours (formerly PNET). Somatic-type malignancies respond poorly to standard germ cell chemotherapy; complete resection can be curative when feasible, with specialist histology-directed treatment for unresectable disease.

---

2. Stage I NSGCTT: Risk Stratification by Lymphovascular Invasion (LVI)

Stage I NSGCTT has no nodal or distant metastases; the primary may have local extension (pT1–pT4), post-orchiectomy serum markers normalize according to expected clearance curves (AFP half-life 5–7 days; beta-hCG 24–36 hours), and staging CT CAP shows no lymphadenopathy or visceral metastases.

The Dominant Prognostic Factor: Lymphovascular Invasion (LVI)

Extensive prospective multicenter trials have established that Lymphovascular Invasion (LVI)—the presence of tumour cells inside intratumoural or peritumoural endothelial-lined lymphatic channels or blood vessels—is the single most powerful, independent predictor of occult retroperitoneal micrometastases:

• LVI-Negative: The risk of occult retroperitoneal metastases and subsequent clinical relapse is approximately 14% to 15% (85% are permanently cured by orchiectomy alone).
• LVI-Positive: The risk of occult retroperitoneal micrometastases and subsequent relapse jumps to approximately 45% to 50%.

LVI and anatomical stage are related but not identical: pT1 is stage IA; pT2–pT4 is stage IB, and local invasion can yield pT2 even without LVI.

Secondary Risk Factors: A high percentage of embryonal carcinoma (>50%) and pathological T-stage (pT2–pT4) further augment risk, but LVI remains the primary guideline-defining variable.

---

3. Clinical Management of Stage I NSGCTT: Surveillance, Adjuvant BEP & RPLND

Following radical inguinal orchiectomy and verification of marker normalization, management pathways diverge based on LVI status:

Management of Low-Risk Stage I NSGCTT (LVI-Negative)

1. Active Surveillance (Preferred Standard per EAU Guidelines):
   • Protocol: EAU minimum surveillance uses markers/review four times in each of years 1–2, twice in year 3, and one to two times yearly in years 4–5. Abdominopelvic MRI/CT is twice in year 1, at 24 months, with 36/60-month imaging discussed; LVI-positive patients may need extra 18-month imaging. Include guideline chest imaging.
   • Rationale: Since 85% of men are already cured, surveillance protects the vast majority from the physical and toxic burdens of chemotherapy or surgery. Relapses require stage- and IGCCCG-adapted treatment, commonly three BEP cycles for good-risk disease; overall stage I cancer-specific survival is approximately 99%.
2. Adjuvant Chemotherapy (1x BEP): An alternative for men unwilling or unsuitable for surveillance. Primary nerve-sparing RPLND has a limited expert-centre role, particularly when chemotherapy is contraindicated and surveillance unacceptable, or with teratoma containing somatic-type malignancy.

Management of LVI-Positive Stage I NSGCTT

1. Adjuvant Chemotherapy with 1 Cycle of BEP (Discuss Alongside Surveillance):
   • Evidence: Landmark prospective trials by the German Testicular Cancer Study Group demonstrated that 1 cycle of BEP (bleomycin 30 mg days 1, 8, 15; etoposide 100 mg/m2 days 1–5; cisplatin 20 mg/m2 days 1–5) reduces the 2-year relapse rate from ~50% down to 1.6% to 2.3%.
   • Toxicity Profile: One cycle limits cumulative exposure compared with multi-cycle chemotherapy but can cause serious acute toxicity, including febrile neutropenia, and gonadal, pulmonary or renal effects. Very long-term cardiovascular and second-cancer risks are not fully defined; discuss sperm banking and follow-up.
2. Active Surveillance: A standard option after counselling about relapse risk approaching 50% and adherence to follow-up. Relapse requires stage-adapted treatment rather than an automatic fixed regimen.
3. Primary Nerve-Sparing RPLND: Resects primary retroperitoneal landing zones. If pathological nodes are negative (pN0), recurrence is <10%; if nodal metastases are identified, discuss surveillance or up to two adjuvant BEP cycles according to pathology and relapse risk; resected teratoma alone does not require chemotherapy. However, primary RPLND is invasive, carries a risk of retrograde ejaculation if sympathetic fibers are damaged, and has largely been superseded by 1x BEP in European practice.

---

4. Metastatic NSGCTT & The Complete IGCCCG Risk Classification

For marker-negative equivocal nodes <2 cm, repeat imaging after about six weeks. Confirmed stage IIA NSGCT with normal markers generally warrants expert nerve-sparing RPLND, whereas marker-positive IIA/B requires IGCCCG-adapted chemotherapy. For disseminated disease, the International Germ Cell Cancer Collaborative Group (IGCCCG) consensus classification categorizes patients into three distinct prognostic tiers that dictate first-line induction chemotherapy:

1. Good Risk NSGCTT (56% of metastatic cases)

• Criteria (ALL must be met):
  • Primary tumour origin: Testicular or retroperitoneal primary, AND
  • Absence of non-pulmonary visceral metastases (NPVM) (pulmonary metastases are permitted!), AND
  • Markers below intermediate-risk thresholds (S0 or S1): AFP < 1,000 ng/mL, beta-hCG < 5,000 IU/L, and LDH < 1.5 × ULN.
• Prognosis: Updated five-year PFS is ~90%; overall survival is ~96%.
• Standard Chemotherapy: 3 cycles of BEP, or 4 cycles of EP when bleomycin is contraindicated.

2. Intermediate Risk NSGCTT (28% of metastatic cases)

• Criteria (ALL must be met):
  • Primary tumour origin: Testicular or retroperitoneal primary, AND
  • Absence of non-pulmonary visceral metastases (NPVM), AND
  • Intermediate Serum Markers (S2): AFP 1,000 to 10,000 ng/mL, OR beta-hCG 5,000 to 50,000 IU/L, OR LDH 1.5 to 10 × ULN.
• Prognosis: Updated five-year PFS is ~78%; overall survival is ~89%.
• Standard Chemotherapy: 4 cycles of BEP, or 4 cycles of VIP with G-CSF when bleomycin is contraindicated.

3. Poor Risk NSGCTT (16% of metastatic cases)

• Criteria (ANY ONE of the following features):
  • Primary tumour origin: Primary Mediastinal Non-Seminomatous Germ Cell Tumour (PMNSGCT), OR
  • Presence of non-pulmonary visceral metastases (NPVM) (e.g., liver, bone, brain), OR
  • Poor Serum Markers (S3): AFP > 10,000 ng/mL, OR beta-hCG > 50,000 IU/L, OR LDH > 10 × ULN.
• Prognosis: In the updated IGCCCG cohort, five-year PFS is ~54% and overall survival ~67%; outcomes vary within the group.
• Standard Chemotherapy: 4 cycles of BEP (or 4 cycles of VIP [etoposide, ifosfamide, cisplatin] with G-CSF if bleomycin is contraindicated).

---

5. Post-Chemotherapy Residual Masses & The Role of Surgery

Following completion of first-line chemotherapy, repeat cross-sectional CT CAP and serum markers are performed to assess response.

The Mandatory Surgical Rule for NSGCTT

Whenever post-chemotherapy cross-sectional imaging reveals a residual retroperitoneal lymph node mass >1.0 cm in transaxial long axis after first-line chemotherapy and markers are normal or normalizing, surgical excision via Post-Chemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) is MANDATORY.

Histological Distribution of Resected Residual Tissue

Histology varies among series and prior regimens. Traditional post-chemotherapy surgical series report approximately:

• 40% to 50%: Fibrosis, necrotic cellular debris, and acellular xanthogranulomatous tissue.
• 35% to 40%: Mature Teratoma (benign-appearing differentiated tissues with malignant potential).
• 10% to 15%: Viable Active Malignant Germ Cell Carcinoma.

Growing Teratoma Syndrome & Somatic Transformation

Because cytotoxic chemotherapy destroys the chemosensitive malignant cells (embryonal, yolk sac, choriocarcinoma) while sparing the chemo-resistant teratoma, teratomatous cells can proliferate post-chemotherapy:

• Growing Teratoma Syndrome: Enlarging masses during or after chemotherapy with normalized AFP/hCG suggest this syndrome; the resected lesion must show mature teratoma without viable malignant germ cell elements to establish it. Left untreated, growing teratomas compress the vena cava, aorta, and ureters, causing bilateral hydronephrosis, intestinal obstruction, and vascular thrombosis.
• Malignant Transformation: Teratoma cells left in situ can develop somatic-type malignancy, such as adenocarcinoma or sarcoma. Resectable disease may still be curable; refer for specialist assessment.

---

6. Surgical Principles of PC-RPLND & Consolidation Chemotherapy

PC-RPLND is an extensive, technically challenging retroperitoneal procedure requiring referral to specialized high-volume tertiary centers:

• Dissection Templates: A full bilateral template extends from the renal arteries to the bifurcation of the common iliac arteries, clearing the paracaval, precaval, interaortocaval, preaortic, and para-aortic nodal basins. Bilateral nerve-sparing RPLND is standard when feasible. A modified ipsilateral template may be considered for selected residuals <5 cm confined to one side on both pre- and post-chemotherapy imaging. Removing only the visible mass (lumpectomy) is inadequate.
• Nerve-Sparing Techniques: Meticulous identification and preservation of the postganglionic sympathetic chains (L1–L3 lumbar splanchnic nerves) and the hypogastric plexus improves the chance of antegrade ejaculation, but preservation depends on disease extent and must not compromise complete resection.
• Adjacent Vascular Resection: Complex adherent or invasive masses may require prosthetic aortic reconstruction, caval resection, or unilateral nephrectomy.
• Adjuvant Consolidation Chemotherapy: Necrosis or teratoma alone requires no further chemotherapy. With incompletely resected viable cancer, two cisplatin-based cycles may be considered in selected patients. Completely resected, low-volume viable cancer—particularly <10% in an initially good-risk patient—may be observed. A >10% finding does not automatically mandate two TIP cycles.

---

IGCCCG Risk Classification & NSGCTT Clinical Management Algorithm